<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727152</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 256</org_study_id>
    <nct_id>NCT03727152</nct_id>
  </id_info>
  <brief_title>Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir</brief_title>
  <official_title>Maintenance of Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir in Virologically Suppressed HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Faculty of Medical Sciences, Radboud University of Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Pharmaceutical care, Faculty of Pharmacy, Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Police General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, multicenter, open-label, single-arm study of 190 virologically
      suppressed HIV-infected adults
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The fundamental principle of regimen switching is to maintain viral suppression without
      jeopardizing future treatment options. The reasons to consider regimen switching in the viral
      suppressed population are to simplify the regimen by reducing the pill burden and dosing
      frequency, to increase the tolerability, reduce the adverse effects as well as long-term
      toxicities, to prevent drug-to-drug interactions and to avoid the dietary requirements.

      Generic TAF/E/D (tenofovir alafenamide 25mg/emtricitabine 200mg/dolutegravir 50 mg), a
      single-tablet once daily regimen, will be an affordable regimen with the potential
      characteristics such as reduced pill burden, less drug to drug interaction and toxicities.
      The generic form (Mylan) is recently received the tentative approval from the U.S. Food and
      Drug Administration (FDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR).
      Whether DTG-containing regimen is a better option than protease inhibitors among
      resource-limited settings during the decisions for second-line treatment options, is needed
      to be evaluated.

      All participants will be switched from their pre-study ART regimen to a single tablet regimen
      (STR) of TAF/FTC/DTG 25/200/50mg once daily.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of subjects with undetectable viral load</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of participants with plasma HIV-1 RNA &lt;50 copies/mL using Snapshot algorithm at week 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants without tolerability failure</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>Proportion of participants without tolerability failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of DTG</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>maximum plasma concentration (Cmax) of DTG 50 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of DTG</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>time to reach maximal concentration (Tmax) of DTG 50 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of DTG</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>area under the curve of a plasma concentration versus time profile (AUC) of DTG 50 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of DTG</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>elimination half life (T1/2) of DTG 50 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ke of DTG</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>elimination rate constant (Ke) of DTG 50 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL of DTG</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>total plasma clearance (CL) of DTG 50 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety at baseline will be compared to level of anxiety at weeks 24 and weeks 48.</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>Anxiety at baseline will be compared to anxiety level at weeks 24 and weeks 48. Anxiety will be assessed using Hospital Anxiety and Depression Scale (HADS). There are 7 different items that assess the level of anxiety of the participants based on a four-point grading scale specific for each item assessed (i.e., I feel tense or 'wound up'; 0 = not at all; 1 = from time to time, occasionally; 2 = a lot of the time; 3 = most of the time). If the total score is between 0-7, then this is considered to be normal. If the total score is between 8-10, then this is considered borderline abnormal (borderline case). If the total score is between 11-21, then this is considered abnormal (case).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression at baseline will be compared to depression level at weeks 24 and weeks 48.</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>Depression at baseline will be compared to depression level at weeks 24 and weeks 48. Depression will be assessed using Hospital Anxiety and Depression Scale (HADS). There are 7 different items that assess the level of depression of the participants based on a four-point grading scale specific for each item assessed (i.e., I still enjoy the things I used to enjoy; 0 = definitely as much; 1 = not quite so much; 2 = only a little; 3 = hardly at all). If the total score is between 0-7, then this is considered to be normal. If the total score is between 8-10, then this is considered borderline abnormal (borderline case). If the total score is between 11-21, then this is considered abnormal (case).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in fasting lipid profiles</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>Changes from baseline in fasting lipid profiles (HDL, LDL, cholesterol, TG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in insulin</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>Changes from baseline in insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in fasting blood glucose levels</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>Changes from baseline in fasting blood glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in renal parameters (creatinine, eGFR)</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>Changes from baseline in renal parameters (creatinine, eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in transient elastography results</measure>
    <time_frame>weeks 24 and weeks 48</time_frame>
    <description>Changes from baseline in transient elastography results</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>generic single tablet regimen of tenofovir alafenamide/e</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HIV infected adults currently on protease inhibitor/ritonavir will switch to use generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir to see if the single tablet can continue to suppress viral replication and be used as a maintenance regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>generic single tablet TAF/FTC/DTG</intervention_name>
    <description>HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir</description>
    <arm_group_label>generic single tablet regimen of tenofovir alafenamide/e</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented HIV-1 infection

          2. Aged â‰¥18 years old

          3. Female participant may be eligible to participate if she:

             is of non-childbearing potential defined as either post-menopausal (12 months of
             spontaneous amenorrhea or &gt;=54 years of age) or physically incapable of becoming
             pregnant with documented tubal ligation, hysterectomy, or bilateral oophorectomy or,
             is of child-bearing potential, with a negative pregnancy test at both Screening and
             week 0 and agrees to use one of the protocol-defined methods of contraception to avoid
             pregnancy.

          4. On current ART for at least 6 months prior to study entry

          5. Current ART includes boosted protease inhibitors

          6. No more than one HIV-1 plasma RNA &gt;50 copies/mL and &lt;200 copies/L (only one 'blip') in
             the past 6 months with a subsequent HIV-1 plasma RNA &lt;50 copies/mL

          7. HIV-1 plasma RNA &lt;50 copies/mL at screening visit

          8. No prior or current exposure to integrase strand transfer inhibitor (INSTI)

          9. Have signed the informed consent form

        Exclusion Criteria:

          1. Breastfeeding female

          2. Pregnancy or positive UPT at screening

          3. Calculated creatinine clearance as estimated by Cockcroft-Gault equation (CrCl) &lt;60
             mL/min,

          4. Alanine aminotransferase (ALT) &gt;2.5 x ULN,

          5. Concomitant use of any of the following medications:

        (1) aluminum and magnesium-containing antacids, proton-pump inhibitors (2) anticonvulsants:
        carbamazepine, oxcarbamazepine, phenobarbital, phenytoin (3) antimycobacterials: rifabutin,
        rifampin, rifapentine (4) St. John's wort

        6. Alcohol or drug abuse that, in the opinion of the investigator, would interfere with
        completion of study procedures

        7. Any serious illness that, in the opinion of the investigator, would interfere with
        completion of study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sivaporn Gatechompol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The HIV Netherlands Australia Thailand Research Collaboration</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>June Ohata, BS</last_name>
    <phone>6626523040</phone>
    <phone_ext>147</phone_ext>
    <email>juneohata4@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HIV-NAT, Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sivaporn Gatechompol, MD</last_name>
      <phone>662 6523040</phone>
      <phone_ext>171</phone_ext>
      <email>sivaporn.k@hivnat.org</email>
    </contact>
    <investigator>
      <last_name>Sivaporn Gatechompol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Police General Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jirayu Visutranukul, MD</last_name>
      <phone>+66 (02) 207 6000</phone>
      <email>nutjv@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Jirayu Visutranukul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 26, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>generic TAF/E/D</keyword>
  <keyword>virologically suppressed HIV-infected adults</keyword>
  <keyword>pharmacokinetics (PK) parameters of DTG</keyword>
  <keyword>psychiatric symptoms</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>ASCVD risk</keyword>
  <keyword>liver fibrosis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

